A forum for researchers, students and applicants in the field of cyclodextrin technology
Chronomodulated diseases demonstrate circadian fluctuations. Conventional dosage forms are inadequate for mitigating these ailments; instead, time-scheduled drug release is necessary
The U.S. Food and Drug Administration has approved Axsome Therapeutics’ new migraine treatment tablet on 30 January 2025 [1]. Marketed
Axsome Therapeutics, Inc., an U.S.-based biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS)
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most widely used classes of medicines in the treatment of inflammation, fever,
Development of generic formulations with cyclodextrins for oral delivery has been neglected for several decades, since the CD-enabled formulations often
